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Summary
Background Eﬀ ective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to 
investigate whether the MUC1 antigen-speciﬁ c cancer immunotherapy tecemotide improves survival in patients with 
stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation.
Methods The phase 3 START trial was an international, randomised, double-blind trial that recruited patients with 
unresectable stage III non-small-cell lung cancer who had completed chemoradiotherapy within the 4–12 week 
window before randomisation and received conﬁ rmation of stable disease or objective response. Patients were 
stratiﬁ ed by stage (IIIA vs IIIB), response to chemoradiotherapy (stable disease vs objective response), delivery of 
chemoradiotherapy (concurrent vs sequential), and region using block randomisation, and were randomly assigned 
(2:1, double-blind) by a central interactive voice randomisation system to either tecemotide or placebo. Injections of 
tecemotide (806 μg lipopeptide) or placebo were given every week for 8 weeks, and then every 6 weeks until disease 
progression or withdrawal. Cyclophosphamide 300 mg/m² (before tecemotide) or saline (before placebo) was given 
once before the ﬁ rst study drug administration. The primary endpoint was overall survival in a modiﬁ ed intention-to-
treat population. This study is registered with ClinicalTrials.gov, number NCT00409188.
Findings From Feb 22, 2007, to Nov 15, 2011, 1513 patients were randomly assigned (1006 to tecemotide and 507 to 
placebo). 274 patients were excluded from the primary analysis population as a result of a clinical hold, resulting in 
analysis of 829 patients in the tecemotide group and 410 in the placebo group in the modiﬁ ed intention-to-treat 
population. Median overall survival was 25·6 months (95% CI 22·5–29·2) with tecemotide versus 22·3 months 
(19·6–25·5) with placebo (adjusted HR 0·88, 0·75–1·03; p=0·123). In the patients who received previous concurrent 
chemoradiotherapy, median overall survival for the 538 (65%) of 829 patients assigned to tecemotide was 30·8 months 
(95% CI 25·6–36·8) compared with 20·6 months (17·4–23·9) for the 268 (65%) of 410 patients assigned to placebo 
(adjusted HR 0·78, 0·64–0·95; p=0·016). In patients who received previous sequential chemoradiotherapy, overall 
survival did not diﬀ er between the 291 (35%) patients in the tecemotide group and the 142 (35%) patients in the 
placebo group (19·4 months [95% CI 17·6–23·1] vs 24·6 months [18·8–33·0], respectively; adjusted HR 1·12, 
0·87–1·44; p=0·38). Grade 3–4 adverse events seen with a greater than 2% frequency with tecemotide were dyspnoea 
(49 [5%] of 1024 patients in the tecemotide group vs 21 [4%] of 477 patients in the placebo group), metastases to 
central nervous system (29 [3%] vs 6 [1%]), and pneumonia (23 [2%] vs 12 [3%]). Serious adverse events with a greater 
than 2% frequency with tecemotide were pneumonia (30 [3%] in the tecemotide group vs 14 [3%] in the placebo 
group), dyspnoea (29 [3%] vs 13 [3%]), and metastases to central nervous system (32 [3%] vs 9 [2%]). Serious immune-
related adverse events did not diﬀ er between groups.
Interpretation We found no signiﬁ cant diﬀ erence in overall survival with the administration of tecemotide after 
chemoradiotherapy compared with placebo for all patients with unresectable stage III non-small-cell lung cancer. 
However, tecemotide might have a role for patients who initially receive concurrent chemoradiotherapy, and further 
study in this population is warranted.
Funding Merck KGaA (Darmstadt, Germany).
Introduction
Lung cancer is the leading cause of cancer-related 
death worldwide, causing about 1·4 million deaths 
each year.1 Non-small-cell lung cancer accounts for 
80–85% of lung cancer cases and 30% of patients 
present with stage III disease.2 Standard treatment for 
patients with a good performance status and 
unresectable stage III non-small-cell lung cancer is 
platinum-based doublet chemotherapy and 
radiotherapy administered with curative intent. A 
meta-analysis of concurrent versus sequential chemo-
radiotherapy showed better outcomes with concurrent 
therapy, but even with concurrent chemo radiotherapy, 
5-year overall survival is just 15%.3
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The mucin 1 (MUC1) glycoprotein is overexpressed 
and abnormally glycosylated in non-small-cell lung 
cancer and other cancers.4,5 Cancer-associated MUC1 is 
involved in abnormal interactions with receptor tyrosine 
kinases and other cell surface receptors. These abnormal 
interactions trigger inappropriate activation of 
intracellular signalling pathways and thus promote the 
growth, proliferation, and survival of cancer 
cells.6–11 Tecemotide (L-BLP25) is a MUC1 antigen-
speciﬁ c immunotherapy capable of inducing a T-cell 
response to MUC1 in both a preclinical MUC1-transgenic 
lung cancer mouse model12 and in patients.13–15 A National 
Cancer Institute (NCI) project to prioritise cancer 
antigens ranked MUC1 very highly on the basis of 
predeﬁ ned criteria.16 In a randomised phase 2 trial of 
tecemotide as maintenance therapy versus best 
supportive care in responding and stable patients with 
stage IIIB or IV non-small-cell lung cancer, a potential 
survival beneﬁ t with tecemotide in stage IIIB patients 
was reported.13,14 A single-arm phase 2 trial of tecemotide 
after chemoradiotherapy for unresectable stage III non-
small-cell lung cancer showed similar survival results.15
On the basis of these promising ﬁ ndings, we initiated 
the START (Stimulating Targeted Antigenic Response To 
non-small-cell lung cancer) study to assess the eﬃ  cacy of 
tecemotide when compared with placebo as a 
maintenance therapy in patients with stage III non-small-
cell lung cancer who have received chemoradiotherapy.
Methods
Study design and participants
START was an international, randomised, double-blind 
phase 3 trial that recruited patients from 33 countries 
worldwide. Eligible patients were those aged 18 years or 
older with histologically or cytologically unresectable 
stage III non-small-cell lung cancer and an Eastern 
Cooperative Oncology Group (ECOG) per formance status 
of 0 or 1. Stage was conﬁ rmed and docu mented by CT, 
MRI, or PET. We did not require patho logical conﬁ rmation 
of mediastinal nodal involve ment and we included all 
histological subtypes of non-small-cell lung cancer. 
Between 4 and 12 weeks before randomisation, patients 
had to have completed at least two cycles of platinum-
based chemotherapy (given sequentially or concurrently) 
with a minimum of 50 Gy of radiation, and have received 
conﬁ rmation of stable disease or an objective response 
after chemoradiotherapy. All patients underwent brain 
imaging during screening to exclude brain metastases. 
Exclusion criteria included: having undergone any 
therapy for lung cancer (other than primary 
chemoradiotherapy), including surgery; receipt of any 
immunotherapy 28 days before randomisation; and 
having metastatic disease or any autoimmune disease. 
Further details of eligibility and exclusion criteria are 
listed in the appendix. 
The study was done in compliance with the principles 
of the International Conference on Harmonisation 
Guidelines on Good Clinical Practice and the Declaration 
of Helsinki. The trial protocol was approved according to 
local regulatory requirements and by each study 
institution’s research ethics board. All patients gave 
written informed consent.
Randomisation and masking  
Patients were randomly assigned on a double-blind basis 
in a 2:1 ratio to receive tecemotide or placebo using a 
central interactive voice randomisation system (Almac, 
Craigavon, Northern Ireland, UK); the interactive voice 
randomisation system staﬀ  assigned patients and were 
not involved in the rest of the trial. Block randomisation 
was used to ensure balanced populations in 24 prespeciﬁ ed 
strata consisting of disease stage (IIIA vs IIIB), response 
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1908 assessed for eligibility
395 not randomly assigned
 324 did not meet inclusion criteria
  25 withdrew consent
   5 had adverse event or symptom 
    deterioration
   4 died
  37 other
   
1513 randomly assigned
97 excluded from primary 
 eﬃcacy analysis population 
 due to clinical hold
177 excluded from primary 
 eﬃcacy analysis population 
 due to clinical hold
1006 assigned to cyclophosphamide and 
 tecemotide (ITT)
 1024 received treatment (includes 
    24 patients who partly received 
    active treatment in error)
   6 did not receive assigned 
    treatment 
   3 withdrawals 
   2 due to clinical hold
   1 received saline and placebo in error
507 assigned to saline and placebo (ITT)
 477 received treatment (includes 1 patient 
    assigned to tecemotide who received 
    placebo)
  31 did not receive assigned treatment
   24 received active treatment in error
        5 withdrawals
        1 due to adverse event 
        1 due to clinical hold
829 were not excluded due to clinical hold 
 (mITT)
410 were not excluded due to clinical hold
 (mITT)
343 discontinued treatment
 274 had disease progression 
  20 had adverse event 
  22 withdrew consent 
  16 died
   3 were lost to follow-up 
   8 other 
671 discontinued treatment
 540 had disease progression 
  49 had adverse event 
  35 withdrew consent 
  27 died 
   5 were lost to follow-up 
  15 other 
  829 assessed in the eﬃcacy analysis 
           (mITT primary analysis population)
1024 assessed in the safety analysis
410 assessed in the eﬃcacy analysis 
 (mITT primary analysis population)
477 assessed in the safety analysis
Figure 1: Trial proﬁ le
ITT=intention-to-treat population. mITT=modiﬁ ed intention-to-treat population, taking into account the 
exclusion of patients randomly assigned within the 6 months preceding the clinical hold.
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to primary chemoradiotherapy (stable disease vs objective 
response), type of primary chemo radiotherapy (con-
current vs sequential), and region (North America 
[Canada, USA] and Australia vs western Europe vs rest of 
world [Mexico, Central and South America, eastern 
Europe, and Asia]). To maintain blinding, tecemotide and 
placebo for the primary and maintenance treatment 
phases were packaged in identical containers. With the 
exception of a designated unblinded statistician on the 
data monitoring board, interactive voice randomisation 
system staﬀ , a designated pharmacist, and a study 
monitor for cyclophosphamide drug accountability 
records, the randomisation code was masked from the 
sponsor and to other individuals monitoring the trial. The 
success of blinding was not formally assessed.
Procedures
After randomisation, and 3 days before administration of 
study drug, one dose of intravenous cyclophosphamide 
(300 mg/m², maximum dose 600 mg) was administered to 
patients assigned to the tecemotide group, and a 
corresponding intravenous saline infusion to patients 
assigned to the placebo group. The rationale for 
incorporating low-dose intravenous cyclophosphamide in 
the tecemotide schedule is based on a trial by MacLean and 
colleagues17 that showed a superior immune response to 
the STn-KLH (Theratope) vaccine in patients with breast 
cancer with intravenous versus oral cyclophosphamide. 
Patients then received tecemotide (contract manufacturer: 
Baxter Pharmaceutical Solutions LLC, Bloomington, IN, 
USA) or placebo (appendix). Tecemotide consists of the 
MUC1-derived 25-aminoacid BLP25 lipopeptide, the 
immunoadjuvant mono phosphoryl lipid A, and three 
liposome-forming lipids (cholesterol, dimyristoyl phos-
phatidyl glycerol, and dipalmitoyl phosphatidyl choline). 
The placebo consisted only of the three liposome-forming 
lipids. Initial therapy consisted of eight consecutive weekly 
sub cutaneous injections of tecemotide (806 μg lipopeptide) 
or placebo. In the absence of progressive cancer or toxicity, 
maintenance tecemotide or placebo every 6 weeks was 
continued until disease progression. Temporary 
suspension of trial treatment because of safety or 
tolerability concerns was allowed at the discretion of the 
investigator, but dose adjustments of tecemotide were not 
permitted.
The primary endpoint was overall survival. Secondary 
endpoints were: time to disease progression, assessed 
Tecemotide 
(N=829)
Placebo
(N=410)
Sex
Men 566 (68%) 280 (68%)
Women 263 (32%) 130 (32%)
Ethnic origin
White 764 (92%) 379 (92%)
Asian or Paciﬁ c Islander 38 (5%) 19 (5%)
Other or missing 27 (3%) 12 (3%)
Age, years 61·0 (19·0–89·0) 61·5 (24·0–83·0)
Smoking status
Current 201 (24%) 99 (24%)
Past 578 (70%) 286 (70%)
Never 50 (6%) 25 (6%)
ECOG performance status
0 398 (48%) 167 (41%)
1 427 (52%) 239 (58%)
Disease stage at ﬁ rst diagnosis
IIIA 327 (39%) 160 (39%)
IIIB 502 (61%) 250 (61%)
Duration of NSCLC, months
Median 6·24 6·14
IQR 5·22–7·49 5·13–7·59
Range 2·8–67·1 2·8–18·4
Histology
Adenocarcinoma 289 (35%) 163 (40%)
Squamous-cell carcinoma 401 (48%) 171 (42%)
Other or unknown 139 (17%) 76 (19%)
Response to initial chemoradiotherapy
Stable disease 265 (32%) 131 (32%)
Objective response 564 (68%) 279 (68%)
Type of initial chemoradiotherapy
Concurrent 538 (65%) 268 (65%)
Sequential 291 (35%) 142 (35%)
Region
North America and Australia 215 (26%) 106 (26%)
Western Europe 319 (38%) 156 (38%)
Rest of world 295 (36%) 148 (36%)
Data are number (%) or median (range), unless otherwise speciﬁ ed. 
ECOG=Eastern Cooperative Oncology Group. NSCLC=non-small-cell lung cancer.
Table 1: Baseline demographic, clinical, and tumour characteristics
Tecemotide (N=829) Placebo (N=410)
Concurrent 
chemoradiotherapy 
(n=538)
Sequential 
chemoradiotherapy 
(n=291)
Concurrent 
chemoradiotherapy 
(n=268)
Sequential 
chemoradiotherapy 
(n=142)
Procedures for staging lymph node involvement*
CT 381 (71%) 246 (85%) 187 (70%) 126 (89%)
MRI 5 (1%) 2 (1%) 5 (2%) 1 (1%)
PET 54 (10%) 14 (5%) 26 (10%) 5 (4%)
PET/CT 111 (21%) 34 (12%) 63 (24%) 15 (11%)
Mediastinoscopy 57 (11%) 18 (6%) 26 (10%) 7 (5%)
Other 48 (9%) 10 (3%) 21 (8%) 5 (4%)
Total tumour dose of radiation delivered with initial chemoradiotherapy, Gy
Mean (SD) 63·4 (5·6) 61·1 (6·5) 63·4 (5·3) 60·8 (5·9)
Median (IQR) 63·8 (60·0–66·0) 60·0 (58·8–66·0) 63·0 (60·0–66·0) 60·0 (58·8–66·0)
Data are number (%) unless otherwise speciﬁ ed. Data are organised by whether patients received concurrent or sequential 
chemoradiotherapy before enrolment in this trial. *The use of more than one mode for N-staging was permitted for each 
patient.
Table 2: Procedures for staging lymph node involvement and radiation dose delivered in the modiﬁ ed 
intention-to-treat population
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(Prof F A Shepherd MD)
Correspondence to:
Dr Charles Butts, Cross Cancer 
Institute, Edmonton, AB, 
T6G 1Z2, Canada  
charles.butts@
albertahealthservices.ca
See Online for appendix
For the trial protocol see http://
www.oncology.med.ualberta.ca/
AboutUs/FacultyMembers/
Documents/CTP%20EMR63325-
001-START%206%200_2%20
signed.pdf
Articles
62 www.thelancet.com/oncology   Vol 15   January 2014
by investigators according to Response Evaluation 
Criteria In Solid Tumors (RECIST) 1.0 with timing of 
follow-up assessments according to the standards of 
each institution; time to symptom progression, 
measured with the Lung Cancer Symptom Scale 
(LCSS); 1 year, 2 year, and 3 year survival; and 
safety.18 The LCSS was assessed before treatment, at 
weeks 2, 5, and 8 of study treatment, and every 6 weeks 
from week 13 until disease progression. It was assessed 
again at 6 and 12 weeks after progression and every 
12 weeks thereafter. Safety was assessed through 
monitoring of adverse events, injection-site reactions, 
vital signs, and laboratory assessments.
The standard deﬁ nition of serious adverse event was 
used as described in the protocol. Severity of adverse 
events were graded according to the NCI Common 
Terminology Criteria for Adverse Events version 3.0.  
Statistical analysis  
We calculated sample size on the basis of a hazard ratio 
(HR) of 0·77 for the primary overall survival outcome 
with 2:1 randomisation, a one-sided α-error of 0·025, and 
statistical power of 90%. Two formal interim analyses 
were planned at 50% and 75% of the planned maximum 
number of events for the ﬁ nal analysis with stopping 
boundaries consistent with an O’Brien-Fleming group-
sequential design. With these assumptions, we needed 
705 deaths for the ﬁ nal analysis. 1322 patients needed to 
have been enrolled within the scheduled accrual and 
follow-up to achieve the 705 events. The primary analysis 
of survival used a Cox proportional hazards regression 
model adjusted for the four stratiﬁ cation variables and 
for multiplicity of tests due to the interim analyses. None 
of the other analyses were adjusted for multiplicity. 
Subgroup analyses by randomisation strata used a Cox 
proportional hazards regression model including 
treatment group only; all other subgroup analyses used a 
Cox proportional hazards regression model adjusted for 
the stratiﬁ cation factors.
In March, 2010, clinical trials of tecemotide, including 
the START trial, were put on hold for enrolment and 
treatment after a case of encephalitis occurred in a 
phase 2 trial of tecemotide for multiple myeloma. 
Subsequent investigations of this patient, an overall 
safety analysis of the use of tecemotide in non-small-cell 
lung cancer, and introduction of safety measures by 
protocol amendment led to the clinical hold being lifted 
in June, 2010. At the time of the clinical hold, we had 
randomly assigned 1182 of the planned 1322 patients. We 
designed a modiﬁ ed intention-to-treat population for the 
primary analysis by prospectively excluding patients 
randomly assigned within the 6 months preceding the 
clinical hold. This approach was based on the assumption 
that a minimum of eight weekly doses and two 6-weekly 
doses (corresponding to about 6 months of treatment) 
were needed for tecemotide to induce an immuno-
therapeutic eﬀ ect on survival. As a result, the sample size 
was adjusted and 274 excluded patients were replaced. 
Furthermore, the accrual and follow-up periods were 
extended by the clinical hold so that 1200 patients were 
needed to observe the anticipated number of events in 
the modiﬁ ed intention-to-treat analyses. The adjusted 
total sample size estimation, 1476, included patients 
excluded from the modiﬁ ed intention-to-treat analysis 
and replacement patients.
This modiﬁ cation of the intention-to-treat population, 
which was based purely on the randomisation time (ie, 
patients were excluded irrespective of whether they were 
on or oﬀ  study treatment), left all other aspects of the 
O’Brien-Fleming group sequential design unchanged 
and did not introduce bias to the analysis. The US Food 
and Drug Administration (FDA) and several European 
regulatory authorities approved the amendment and 
modiﬁ cation of the intention-to-treat population before 
the analysis.
Figure 2: Overall survival in the modiﬁ ed intention-to-treat population, and by randomisation strata
(A) Kaplan-Meier curve of overall survival in the primary analysis (modiﬁ ed intention-to-treat) population. 
(B) Overall survival in each of the four randomisation strata in the modiﬁ ed intention-to-treat population. 
HR=hazard ratio. *Number in parentheses show number at risk.
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We used the statistical analysis system SAS 
(version 9.1.3) for analyses and S+SeqTrial (version 2) for 
the adjustment of the results of the primary analysis, 
accounting for the two interim analyses as part of the 
group sequential design.
This study is registered with the European Union drug 
regulating authorities Clinical Trials (EudraCT) database, 
number 2006-000579-14, and with ClinicalTrials.gov, 
number NCT00409188.
Role of the funding source  
Merck KGaA, the study sponsor, designed the trial in 
collaboration with the investigators. The sponsor developed 
the protocol and statistical analysis plan, provided the 
study drug, coordinated the management of study sites 
and the clinical data management, did statistical analyses, 
and participated in the interpretation of data. CB, FAS, AS, 
and CH had full access to the raw data. CB and FAS wrote 
the initial draft manuscript and incorporated revisions and 
had the ﬁ nal responsibility for the decision to submit for 
publication. 
Results
From Feb 22, 2007, until Nov 15, 2011, 1513 patients were 
enrolled from 264 centres in 33 countries worldwide 
(ﬁ gure 1; appendix). The modiﬁ ed intention-to-treat 
primary analysis population consisted of 1239 patients 
after exclusion of 274 patients randomly assigned within 
the 6 months preceding the clinical hold. Only eight (1%) 
of 1239 patients were lost to follow-up during the 
treatment phase (ﬁ gure 1).
At the time of implementation of the clinical hold in 
March, 2010, 531 patients were receiving study treatment. 
Although the clinical hold was lifted in June, 2010, 
resumption of treatment with tecemotide or placebo only 
started after local regulatory approval of the amended 
trial protocol after a median suspension of 135 days (IQR 
127–174; range 92–358). Of these 531 patients, 180 did not 
resume treatment.
The two groups were evenly matched for important 
characteristics such as age, sex, stage at diagnosis, and 
response to initial chemoradiotherapy (table 1), and 
procedures for staging of the nodal status and delivery of 
chemoradiotherapy (table 2), although a numerical 
diﬀ erence in histology results was noted.
At the time of the clinical cutoﬀ  for data collection of 
Aug 8, 2012, 469 (57%) of 829 patients in the tecemotide 
group had died compared with 237 (58%) of 410 patients in 
the placebo group (modiﬁ ed intention-to-treat 
population); one death in the tecemotide group was 
excluded from the eﬃ  cacy analysis because only the year 
was reported. Median follow-up was 39·9 months (IQR 
21·2–48·7) in the tecemotide group and 37·7 months 
(19·9–49·7) in the placebo group. The diﬀ erence in 
median overall survival between groups was not 
statistically signiﬁ cant (25·6 months [95% CI 22·5–29·2] 
in the tecemotide group vs 22·3 months [19·6–25·5] in 
the placebo group; HR 0·88 [0·75–1·03], p=0·123 
[stratiﬁ ed model, multiplicity adjusted]; ﬁ gure 2A). 
Survival at year one, year two, and year three are also 
presented in ﬁ gure 2A. Although a numerical imbalance 
was noted between groups on the basis of histology, 
adjustment for histology did not change the treatment 
eﬀ ect (HR 0·88 [95% CI 0·76–1·03]; p=0·126).
In the 177 patients in the tecemotide group and the 
97 patients in the placebo group who were excluded 
because of the clinical hold, no beneﬁ t in median overall 
survival was seen with tecemotide (26·4 months [95% CI 
B Overall survival in subgroups of patients who received concurrent chemoradiotherapy
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Figure 3: Overall survival in patients who received concurrent chemoradiotherapy
(A) Kaplan-Meier curve of overall survival in the subgroup of patients who received initial concurrent 
chemoradiotherapy. (B) Overall survival by baseline characteristics in the concurrent chemoradiotherapy subgroup. 
ECOG PS=Eastern Cooperative Oncology Group performance status. HR=hazard ratio.
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21·4–not reached] with tecemotide vs 28·1 [21·7–not 
reached] with placebo; HR 1·09 [0·75–1·56], p=0·663; 
appendix). Our sensitivity analysis to assess the potential 
eﬀ ect of the clinical hold suggested that the hold had a 
negative impact on the treatment eﬀ ect of tecemotide in 
terms of survival that extended beyond the 6 months 
selected for in the primary analysis population 
(appendix).
Preplanned subgroup analyses for the stratiﬁ cation 
variables showed no signiﬁ cant diﬀ erence between 
patients assigned to tecemotide and placebo, except for 
those patients who received concurrent chemo radio-
therapy (ﬁ gure 2B). Of the 806 patients who received 
concurrent chemoradiotherapy, median overall survival 
for the 538 (67%) patients assigned to tecemotide was 
notably increased compared with the 268 [33%] patients 
assigned to placebo (HR 0·78 [95% CI 0·64–0·95], 
p=0·016; ﬁ gure 3A). A beneﬁ t from tecemotide was seen 
in some predeﬁ ned subgroups (of suﬃ  cient size, deﬁ ned 
as >100 patients) of patients treated with concurrent 
chemoradiotherapy (ﬁ gure 3B; appendix). The interaction 
test supported the link between delivery of 
chemoradiotherapy and treatment eﬀ ect (pinteraction=0·032). 
We noted no diﬀ erence in median overall survival 
between treatment groups in the 433 patients who 
received sequential chemoradiotherapy (HR 1·12 [95% CI 
0·87–1·44], p=0·38; ﬁ gure 4A) and subgroup analyses 
showed heterogeneous results (ﬁ gure 4B; appendix). The 
Cox regression analysis of overall survival when adjusted 
for baseline ECOG performance status and 
randomisation strata (HR 0·90 [95% CI 0·77–1·06]; 
p=0·21) was not notably diﬀ erent from the primary 
analysis result adjusted for randomisation strata only 
(HR 0·89 [0·76–1·04]; p=0·16).
Time to symptom progression, as assessed by the 
LCSS, diﬀ ered only numerically between the tecemotide 
group and the placebo group (HR 0·85 [95% CI 
0·73–0·98]; p=0·023; ﬁ gure 5A), and the same was true 
for median time to disease progression (HR 0·87 
[0·75–1·00]; p=0·053; ﬁ gure 5B); however, this numerical 
diﬀ erence requires conﬁ rmation.
The most common treatment-emergent adverse events 
are shown in table 3, and an overview of all adverse 
events is presented in table 4. The proportions of adverse 
events were similar between the tecemotide and placebo 
groups in nearly every adverse event category. Adverse 
events of any grade that were more than three percentage 
points more frequent in the tecemotide group compared 
with the placebo were cough, back pain, nausea, chest 
pain, nasopharyngitis, arthralgia, and myalgia (appendix). 
The reported frequencies of adverse events of special 
interest, including injection-site reactions and ﬂ u-like 
symptoms, were slightly more frequent in the tecemotide 
group than in the placebo group and were generally mild 
to moderate in severity (grade 1 or 2; appendix). 
Potentially immune-related diseases were infrequent 
(<3%) and not diﬀ erent between groups (appendix).
One fatal treatment-emergent adverse event of hepatic 
failure was assessed as being potentially related to study 
treatment. Two other patients had fatal adverse events 
that were assessed as being potentially related to study 
treatment, but occurred more than 42 days after the last 
dose (one with nervous system disorder, and one with a 
combination of sepsis, pneumonia, and thrombo-
cytopenia), and there was one death of unknown cause. 
No safety signal could be established from these events 
after a review of all safety data.
Figure 4: Overall survival in patients who received sequential chemoradiotherapy
(A) Kaplan-Meier curve of overall survival in the subgroup of patients who received initial sequential 
chemoradiotherapy. (B) Overall survival by predeﬁ ned baseline characteristics in the sequential chemoradiotherapy 
subgroup. ECOG PS=Eastern Cooperative Oncology Group performance status. HR=hazard ratio.
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Treatment delivery was similar between the groups. One 
patient in each treatment group did not receive the full 
dose of cyclophosphamide or saline and six patients in 
each treatment group did not receive tecemotide or placebo 
after administration of cyclophosphamide or saline. 
93 (9%) of 1024 patients who received tecemotide and 45 
(9%) of 477 patients who received placebo had a treatment-
related adverse event causing temporary discontinuation 
of trial treatment, and 178 (17%) and 83 (17%) patients in 
the tecemotide and placebo groups, respectively, had an 
adverse event leading to permanent discontinuation of 
trial treatment. 20 (2%) patients in the tecemotide group 
and seven (1%) in the placebo group had adverse events 
judged to be related to study drug that led to permanent 
discontinuation. 160 (16%) and 79 (17%) patients in the 
tecemotide and placebo groups, respectively, had adverse 
events that were not regarded as related to study drug but 
that led to permanent discontinuation.
Discussion
The results of the START trial—the largest done, to our 
knowledge, in the setting of stage III non-small-cell lung 
cancer (panel)—showed that the primary endpoint of 
overall survival in patients who received cyclophos-
phamide and tecemotide after chemo radiotherapy did 
not diﬀ er signiﬁ cantly from those who received saline 
and placebo after chemo radio therapy. However, we noted 
a favourable eﬀ ect of tecemotide in patients who received 
concurrent chemoradiotherapy, with a 10·2 month 
improvement in median survival. By contrast, no beneﬁ t 
was seen in the sequential chemoradiotherapy subgroup. 
Therefore, although our primary endpoint was not met, 
and the null hypothesis was not rejected, our results 
suggest that tecemotide might have a potential beneﬁ t as 
a maintenance therapy after initial concurrent chemo-
radiotherapy in patients with non-small-cell lung cancer.
Continuing follow-up will assess the eﬀ ects of 
tecemotide on long-term survival. Additionally, a smaller 
phase 3 trial (INSPIRE),23 assessing tecemotide in Asian 
patients with stage III non-small-cell lung cancer, will 
restrict recruitment to patients receiving concurrent 
chemoradiotherapy.23
At the time of the clinical hold, accrual was 90% 
complete and 531 patients were receiving investigational 
treatment. By the time the amended protocol was 
approved by local authorities and treatment could resume, 
patients had been without study medication for a median 
of 135 days and a third never resumed study treatment, 
mostly because of disease progression. We postulated 
that the interruption of therapy would have the greatest 
eﬀ ect in patients who were closest to the primary phase of 
the immunotherapy at the time of the hold. We deﬁ ned 
the primary analysis population prospectively to try to 
account for the clinical hold by excluding patients 
randomly assigned within the 6 months preceding the 
hold, on the basis of theoretical considerations related to 
the mode of action of tecemotide. This assumption is 
supported by general considerations about treatment 
time with tumour immunotherapeutics as laid out in the 
FDA guidance for the development of such 
compounds.24 Indeed, those patients who were within 
6 months of randomisation at the time of the hold had no 
beneﬁ t from tecemotide. However, further sensitivity 
analyses suggested that, despite these attempts to 
compensate for the clinical hold, the treatment 
interruption nonetheless perhaps negatively biased the 
overall survival results towards an underestimated 
treatment eﬀ ect of tecemotide (appendix).
Interpretation of the results of the START trial has 
limitations inherent to the trial design. START was 
done on a global scale and therefore allowed for 
ﬂ exibility of inclusion on the basis of variation of 
standards for the initial treatment of stage III non-
small-cell lung cancer in the 33 diﬀ erent countries 
involved (appendix). As a result, our reported ﬁ ndings 
take into account the diﬀ erent treatment strategies used 
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Figure 5: Time to symptom progression and time to progression in the modiﬁ ed intention-to-treat 
population
Kaplan-Meier curves of the secondary endpoints time to symptom progression (A) and of time to progression 
(B) in the primary analysis (modiﬁ ed intention-to-treat) population. HR=hazard ratio.
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in diﬀ erent centres. Additionally, because patients were 
only eligible after completion of initial chemo-
radiotherapy, data for radiotherapy schedule and 
technique, including dose volume data, were not 
obtained to the same extent as in other chemo-
radiotherapy trials (eg, RTOG 061719) and quality 
assurance of radiotherapy was not undertaken, with the 
exception of source data veriﬁ cation. However, the 
mode of delivery of initial chemoradiotherapy was a 
stratiﬁ cation variable and a subgroup analysis based on 
this variable was prespeciﬁ ed in the protocol. Patients 
enrolled from North America and Australia almost 
exclusively received concurrent chemoradiotherapy, 
whereas most patients enrolled from eastern European 
sites received sequential chemoradiotherapy. At the 
time START was designed, little information was 
available about survival of patients with stage III non-
small-cell lung cancer who had at least stable disease 
after initial chemoradiotherapy. To establish a 
reasonable estimate for survival in the placebo group, 
more than 200 lung cancer specialists were surveyed. 
Subsequent reports from the Hoosier Oncology 
Group20 and the SWOG 002325 trials suggest that the 
20 month median survival estimate for the control 
group in START was an accurate estimate. Finally, 
interpretation of these results is aﬀ ected by the outcome 
of the clinical hold. For example, the patients who were 
followed up for longer than planned because of the 
clinical hold increase the precision of the Kaplan-Meier 
curve at the later timepoints, whereas the patients 
recruited later have a relatively short follow-up time 
with a minimum of about 9 months. We took reasonable 
steps to deﬁ ne the modiﬁ ed intention-to-treat population 
without knowledge of the actual survival outcome to 
minimise any bias introduced by these changes. This 
prospective change of the primary analysis set was 
made in consultation with regulatory agencies.
Although the results of this trial need conﬁ rmation, a 
number of hypotheses can be oﬀ ered as to why active 
antigen-speciﬁ c immunotherapy might show a 
favourable eﬀ ect in patients treated with concurrent 
and not sequential chemoradiotherapy. Results of an 
in-vitro study using a head and neck model cell 
line26 showed that cytotoxic T-cell mediated lysis 
directed against MUC1 was enhanced by previous 
treatment with concomitant chemoradiotherapy com-
pared with either modality alone. Additionally, two 
studies by similar study teams27,28 reported that some 
chemotherapeutic agents can induce immuno genic cell 
death whereas others induce tolero genic cell death. 
Formenti and Demaria29 recently postulated that the 
success of con current chemo radiotherapy in diﬀ erent 
solid tumours might be explained by achievement of 
immuno genic cell death.29 Indeed, our preliminary 
analysis of beneﬁ t by regimen seems to support this 
hypothesis, suggesting a greater survival beneﬁ t from 
tecemotide than with placebo in the concurrent 
chemoradiotherapy group with some chemotherapeutic 
agents (eg, vinorelbine and taxanes) than with others 
(eg, etoposide; appendix). However, this analysis should 
be regarded as exploratory only.
Tecemotide (N=1024) Placebo (N=477)
Total Grade 1–2 Grade 3 Grade 4 Total Grade 1–2 Grade 3 Grade 4
Cough 338 (33%) 323 (32%) 15 (1%) 0 133 (28%) 126 (26%) 7 (1%) 0
Dyspnoea 238 (23%) 189 (18%) 42 (4%) 7 (1%) 112 (23%) 91 (19%) 17 (4%) 4 (1%)
Fatigue 197 (19%) 186 (18%) 11 (1%) 0 102 (21%) 92 (19%) 10 (2%) 0
Back pain 146 (14%) 130 (13%) 14 (1%) 2 (<1%) 53 (11%) 50 (10%) 3 (1%) 0
Nausea 140 (14%) 140 (14%) 0 0 39 (8%) 39 (8%) 0 0
Chest pain 135 (13%) 123 (12%) 11 (1%) 1 (<1%) 45 (9%) 40 (8%) 4 (1%) 1 (<1%)
Nasopharyngitis 128 (13%) 127 (12%) 1 (<1%) 0 44 (9%) 44 (9%) 0 0
Headache 124 (12%) 120 (12%) 4 (<1%) 0 54 (11%) 53 (11%) 1 (<1%) 0
Decreased appetite 109 (11%) 102 (10%) 7 (1%) 0 44 (9%) 42 (9%) 2 (<1%) 0
Arthralgia 108 (11%) 104 (10%) 4 (<1%) 0 34 (7%) 31 (6%) 3 (1%) 0
Data are number of patients who had at least one event (% of patients). Adverse events were classiﬁ ed into grades 1–4; adverse events for which the maximum grade was 
missing are included in the columns of total grades.
Table 3: Summary of treatment-emergent adverse events occurring in more than 10% of the safety population
Tecemotide 
(N=1024)
Placebo
(N=477)
Any adverse event 938 (92%) 432 (91%)
Any adverse event related to study drug 353 (34%) 129 (27%)
Any serious adverse event 303 (30%) 151 (32%)
Any serious adverse event related to study drug 16 (2%) 5 (1%)
Any grade 3 or 4 adverse event 342 (33%) 171 (36%)
Any grade 3 or 4 adverse event related to study drug 15 (1%) 5 (1%)
Any adverse event leading to death 46 (4%) 35 (7%)
Any adverse event relating to study drug leading to death 1 (<1%) 0
Data are number of patients who had at least one event (% of patients).
Table 4: Overview of all adverse events in the safety analysis population
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Patient selection is another possible factor for the 
diﬀ erences in overall survival seen in patients receiving 
concurrent compared to sequential chemoradiotherapy. 
Patients selected for sequential chemoradiotherapy 
might have had a poorer performance status at the start 
of initial treatment and a more compromised immune 
system than those allocated to concurrent chemoradio-
therapy, which requires a good performance status. Data 
for performance status at the time of initial chemo-
radiotherapy were not obtained because patients were 
enrolled only after conﬁ rmation of response. The 
eligibility criteria required only that the performance 
status at the time of randomisation be 0–1. Patients who 
received concurrent chemoradiotherapy could have had 
smaller primary tumours than patients who received 
sequential chemoradiotherapy, since delivery of 
concurrent chemoradiotherapy is diﬃ  cult in the setting 
of a very large primary tumour. The bulky primary 
tumour might be a less favourable setting for immuno-
therapy. Data to support or refute these hypotheses in the 
context of the START study are not available.
Although RECIST 1.0 had to be followed for 
classiﬁ cation of disease progression, no formal imaging 
schedule was required after randomisation in START; 
rather, it was done according to institutional practice. 
Symptomatic progression was assessed more formally 
using the LCSS. Both progression-related endpoints 
(time to symptom progression and time to progression) 
diﬀ ered numerically between patients assigned to 
tecomotide and those assigned to placebo; however, these 
numerical diﬀ erences need conﬁ rmation.
In this trial the safety analysis set consisted of 
1024 patients who received tecemotide, 372 (36%) of 
whom received it for more than 52 weeks. These analyses 
conﬁ rmed the favourable safety and tolerability proﬁ le of 
tecemotide. There were no clinically concerning 
diﬀ erences between tecemotide and placebo for any 
adverse event. Adverse events of special interest such as 
injection-site reactions or ﬂ u-like symptoms were 
infrequent and rarely greater than grade 2. Potential 
immune-related diseases or events were seen in less than 
3% of patients and with similar frequency in the two 
groups.
In conclusion, although survival was not signiﬁ cantly 
prolonged with tecemotide overall in patients with 
stage III non-small-cell lung cancer, we believe the 
results seen in the predeﬁ ned subgroup of patients who 
received concurrent chemoradiotherapy are suggestive of 
a beneﬁ t of tecemotide in this population and warrant 
further study. A conﬁ rmatory randomised trial of 
tecemotide is being planned for patients with stage III 
non-small-cell lung cancer after concurrent chemoradio-
therapy.
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